Adam Lauver, PhD

he/his/him
Associate Professor
Pharmacology & Toxicology

Bio

I am a pharmacologist at Michigan State University, where I lead research focused on cardiovascular pharmacology, drug discovery, and pharmacokinetics. My work explores the vascular effects of antiplatelet therapies, particularly clopidogrel, and investigates novel drug candidates for cardiovascular and infectious diseases. As director of the MSU Certara Center of Excellence, I integrate computational modeling with experimental pharmacology to optimize drug development. Through industry collaborations and NIH-funded projects, my research advances translational pharmacology with the goal of improving therapeutic outcomes.

Colleges

• College of Veterinary Medicine

Programs

• Integrated Pharmacological Sciences Training Program
• Doctor of Philosophy in Pharmacology and Toxicology

Education

• Postdoctoral, Pharmacology, University of Michigan (2007—2011)
• Ph.D., Pharmacology, University of Michigan (2002—2007)
• B.S., , Pennsylvania State University (1997—2001)

Funding

• Perivascular Adipose Tissue (PVAT) as a Central Integrator of Vascular Health, National Heart Lung and Blood Institute (2021-12-22—2026-11-30)

Works

• Single-nucleus analysis of thoracic perivascular adipose tissue reveals critical changes in cell composition, communication, and gene regulatory networks induced by a high fat hypertensive diet. (2025-02-14)
• The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis. Clinical and Translational Science (2023)
• Improving corrected QT; Why individual correction is not enough. Journal of Pharmacological and Toxicological Methods (2022)
• Pleiotropic effects of clopidogrel. Purinergic Signalling (2022)
• QT Ratio: A simple solution to individual QT correction. Journal of Pharmacological and Toxicological Methods (2022)
• Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery. European Journal of Pharmacology (2021)
• Clopidogrel treatment inhibits P2Y₂-Mediated constriction in the rabbit middle cerebral artery. European Journal of Pharmacology (2021)
• DT‐678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists. Pharmacology Research & Perspectives (2019)
• DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y₁₂ antagonists. Pharmacology Research and Perspectives (2019)
• Relationship of clinical adverse event reports to models of arrhythmia risk. Journal of Pharmacological and Toxicological Methods (2019)
• Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. The Journal of pharmacology and experimental therapeutics (2016)
• Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosiss. Journal of Pharmacology and Experimental Therapeutics (2016)
• Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury. PloS one (2014)
• Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury. PLoS ONE (2014)
• CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel. Thrombosis and haemostasis (2014)
• CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of Clopidogrel. Thrombosis and Haemostasis (2014)
• Oral pretreatment with liposomal glutathione attenuates reperfusion injury in rabbit isolated hearts. Journal of cardiovascular pharmacology (2013)
• Oral pretreatment with liposomal glutathione attenuates reperfusion injury in rabbit isolated hearts. Journal of Cardiovascular Pharmacology (2013)
• Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel. Molecular pharmacology (2013)
• Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel. Molecular Pharmacology (2013)
• Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proceedings of the National Academy of Sciences of the United States of America (2010)
• Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology (2008)
• Sulodexide: A renewed interest in this glycosaminoglycan. Cardiovascular Drug Reviews (2006)
• Disodium disuccinate astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. Journal of Pharmacology and Experimental Therapeutics (2005)
• Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. Journal of Pharmacology and Experimental Therapeutics (2005)
• Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. Journal of Pharmacology and Experimental Therapeutics (2002)

Employment

• Associate Professor, Michigan State University (2016-11-01)
• Research Assistant Professor, University of Michigan (2011—2016)
• , Bristol-Myers Squibb Co (2001—2002)